Black Diamond Therapeutics is an oncology medicine company focusing on the discovery and development of small molecule, MasterKey therapies. Co.'s proprietary technology platform, which it refers to as its Mutation-Allostery-Pharmacology drug discovery engine, is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Co. has designed its clinical-stage product candidates, BDTX-1535 and BDTX-189, to selectively inhibit families of oncogenic mutations which occur across a range of tumor types that affect the ErbB-1 epidermal growth factor receptor. We show 17 historical shares outstanding datapoints in our BDTX shares outstanding history coverage, used to compute BDTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BDTX market cap history over the course of time is important for investors
interested in comparing BDTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BDTX versus a peer is one thing; comparing
BDTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BDTX can fluctuate over the course of history.
With this page we aim to empower investors researching BDTX by allowing them to research the BDTX market cap history. |
Free BDTX Email Alerts:
Video: The Importance of Market Cap
